Vildagliptin
- 132 trials, 3 about aging, 102 with no results posted
- 92 of 132 trials sponsored by its developers
- Human trial1
- Humans1
Trials
3 about aging, of 132About aging
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
Phase 3Completed
Phase 4Completed
Phase 3Completed
Approved
Sep 25, 2007Diabetes Mellitus, Type 2, Diabetes
Nov 19, 2008Diabetes Mellitus, Type 2, Diabetes
Nov 19, 2008Diabetes Mellitus, Type 2, Diabetes
Repurposing
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 4Results posted19 trials
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 4Completed1 trial
All 25Fewer
Phase 4Status unknown1 trial
Phase 4Completed5 trials
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 4Status unknown1 trial
Phase 4Results posted5 trials
Phase 4Completed2 trials
Phase 4Completed1 trial
Phase 4Completed6 trials
Phase 3Completed3 trials
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 3Completed1 trial
Phase 4Status unknown4 trials
Phase 4Completed1 trial
Phase 2Completed1 trial
Phase 2Completed1 trial
Multiple endocrine neoplasia type 1
Phase 2Completed1 trial
Every condition in trials
Fasting
Phase 4Completed1 trial
Fed condition
Phase 1Completed1 trial
Stopped
NCT01910441TerminatedType 2 diabetes
The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.
Trial sponsors
Novartis Pharmaceuticals Corporation
Company49 trialsPhase 425,066 people
Company41 trialsPhase 48,428 people
Company1 trialPhase 4266 people
Company1 trialPhase 4120 people
Company1 trialPhase 444 people
Company1 trialPhase 3162 people
Company1 trialPhase 3106 people
Company2 trialsPhase 147 people